Investigating the Effect of Low-dose Extended-release Tacrolimus and Sirolimus on the Short-term Outcomes of Allograft Kidney Transplantation
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• All Kidney transplant recipients
Locations
Other Locations
Islamic Republic of Iran
Nooshin Dalili
RECRUITING
Tehran
Contact Information
Primary
PI
dr.nooshindalili@gmail.com
00989122404331
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2026-07-01
Participants
Target number of participants: 50
Treatments
No_intervention: Standard of care
Advograf plus Cellcept plus Prednisolone
Other: Intervention
Advograf plus Rapamiune plus Prednisolone
Related Therapeutic Areas
Sponsors
Leads: Shahid Beheshti University of Medical Sciences